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Cystic and alveolar echinococcosis are diseases of animals and humans caused by the larval
stage of tapeworms in the genus Echinococcus. Cystic echinococcosis (CE), caused by E. granu-
losus sensu lato and alveolar echinococcosis (AE), caused by E. multilocularis, have a substan-
tial public health impact globally. Both conditions are considered neglected tropical diseases
(NTDs) and neglected zoonotic diseases (NZDs), and prioritized by the World Health Organi-
zation (WHO) (http://www.who.int/neglected_diseases/diseases/en/). Within the last 10 years,
advancements have taken place in Echinococcus biology and genetics, including the delineation
of new species within E. granulosus sensu lato [1] and full sequencing of E. granulosus sensu
stricto and E. multilocularis [2]. Consequently, researchers are now provided with new tools to
better understand parasite biology and host-parasite interactions, with the goal of opening
new avenues for therapy [2].
Although often discussed together, CE and AE are two distinct chronic diseases, with CE
considered mainly a disabler, while AE is fatal if left untreated [3]. Clinical manifestations of
human CE typically result from the growth of single or multiple cysts in the liver, lungs, and/
or other organs that can eventually produce a mass effect and impair organ function. Treat-
ment usually consists of a watch-and-wait approach, albendazole administration, and/or surgi-
cal (general or percutaneous/perendoscopic) intervention, depending on the stage, integrity,
number, size, and location of cysts [4]. In contrast, AE acts more like an invasive tumor, which
manifests predominantly in the liver, but can infiltrate adjacent organs and tissues and pro-
duce distant metastases [3, 5]. Cure can be achieved by radical surgery, including ex-vivo liver
resection [6]. However, most patients are not surgical candidates at the time of diagnosis and
receive life-long albendazole therapy [3, 7, 8].
A substantial obstacle to controlling CE and AE is lack of data on the number of cases
locally and globally. During the last decade, great strides have been made in improving the
amount and quality of collected case data. Large-scale census studies have been conducted in
China since the 1990s [9]. The first formal initiative to collect data on human AE was the Euro-
pean Echinococcosis Registry (EurEchinoReg), launched in 1997 [5]. Recently, the European
Commission funded a collaborative and translational project (HERACLES: Human cystic
Echinococcosis ReseArch in CentraL and Eastern Societies; http://www.heracles-fp7.eu/) to
assess the ultrasound prevalence of CE in rural areas of Eastern Europe and adjacent countries,
create an online prospective multi-center European Register of CE cases (ERCE) [10], and
improve available serological and therapeutic tools as well as molecular diagnostics.
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Building on enhanced case registration, strides have been made towards obtaining im-
proved estimates of the burden of both CE and AE. Initial global estimates are now available
for both conditions [11, 12]. More recently, two large-scale burden of disease initiatives, the
global burden of foodborne diseases project overseen by the WHO and the Global Burden of
Disease (GBD) Study, have included Disability Adjusted Life Year (DALY) estimates for echi-
nococcosis. The WHO study estimated an echinococcosis (AE and CE combined) burden of
approximately 871,000 DALYs in 2010. Of this total, approximately 184,000 DALYs (equating
to 188,000 new cases per year) and 688,000 DALYs (equating to 18,400 new cases per year)
were attributable to CE and AE, respectively. For the year 2013, the GBD Study estimated a
similar number of DALYs for CE and there is currently no GBD estimate for AE [3]. While
there were differences in how these two initiatives approached filling epidemiologic data gaps
(e.g., lack of data on infection frequency), the generated preliminary values allow for a starting
point from which to improve burden estimates as these gaps are filled.
In order to improve case recording worldwide and ensure the appropriate management of
patients, accurate diagnostics are needed. In this regard, the main advances have been achieved
by the combination of serological tests and functional imaging to monitor response to treat-
ment [3, 4, 7] and the use of molecular identification and species characterization in difficult
cases [13]. Although antibodies against antigen B or antigen 5 show a higher sensitivity, crude
parasite extracts (e.g., hydatid fluid) continue to be most widely used for antibody detection
for CE cases [13]. Lack of test accuracy remains a critical issue for the diagnosis of CE, espe-
cially during community screenings. Despite the use of the highly E. multilocularis-specific
Em2 and Em18 antigens, cross-reactivity remains a problem and source of misinterpretation
in areas where CE and AE co-exist [13].
Over the last decade, a structured cyst stage-specific approach to patient management has
been recommended based on the WHO-International Working Group on Echinococcosis cyst
classification scheme, which was officially adopted in 2010 [4]. Globally, there has been a push
for physicians to take a patient’s clinical condition, technical capability of the healthcare facil-
ity, safety and effectiveness of the approach, and the cost of treatment into account when devis-
ing a treatment plan, with management of AE especially complex [3, 8]. Unfortunately, for
both diseases, prospective studies to guide evidence-based therapeutic strategies are lacking
and the adoption of a stage-specific approach by physicians has been slow [3]. In addition,
whatever treatment plan is selected, long-term follow-up should be mandatory in order to
detect recurrences [3, 4].
Control program implementation for CE has historically relied on a combination of local
education regarding slaughter and hygiene practices and dog population management and/or
deworming initiatives using praziquantel. The development of vaccines targeting sheep inter-
mediate hosts has now added a new tool to combat CE in highly impacted populations. The
EG 95 vaccine has been tested in a number of countries, including China and Argentina with
promising results [9, 14]. Control program evaluation relies on surveillance for the pathogen
in domestic dogs and ruminants, which is costly and labor-intensive. Overall, the prevalence
of human CE has been reduced in areas where long-term intensive control programs have
been put in place. However, in most resource-poor areas, CE control remains a challenge [9].
Compared to CE, control measures for AE are more logistically challenging due to the pres-
ence of wildlife hosts. Researchers are working to better understand the ecology of wildlife
definitive (e.g., foxes and other wild canids) and intermediate (e.g., small mammals) hosts, to
predict risks for human infection and improve anthelminthic baiting practices in rural and
urban areas [9].
While progress has been made in reporting, diagnosis, treatment, and control, CE and AE
are still very much neglected diseases. Albendazole availability and/or cost continue to be a
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005477 April 20, 2017 2 / 4
problem in both socioeconomically disadvantaged and high-income countries. In addition, at
present, there are no alternative drugs for patients with AE who experienced severe side effects
and cannot be treated with albendazole (or mebendazole). Therefore, additional research into
new therapeutic agents is needed [2]. The chronic nature of CE and AE and a strong reliance
on advanced imaging for diagnosis continues to impact the speed of case detection in socio-
economically disadvantaged communities. Occurrence of AE as an opportunistic infection in
patients with therapeutic immune suppression may have worrisome consequences in the near
future [3, 15]. Going forward, control will continue to rely on taking a One Health approach,
involving physicians, veterinarians, ecologists, social scientists, laboratory scientists, and oth-
ers. We encourage the scientific community to perform prospective collaborative studies and
policymakers to promote new drug development and improved case notification. The echino-
coccosis community moves into the next decade proud of their achievements, but realizing
that there is still much work remaining.
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